Faldaprevir Regimen Effective as First Treatment for HCV Genotype 1

Major finding: Relative to peers given placebo, patients given faldaprevir had a significantly higher rate of sustained virologic response at 12 weeks after the end of treatment (79%-80% vs. 52%).

Data source: A randomized phase III trial among 652 patients with treatment-naive chronic HCV genotype 1 (STARTverso 1 trial).

Disclosures: Dr. Moreno disclosed that he is a board member for Janssen, Gilead, MSD, and Bristol-Myers Squibb; he is a consultant for Janssen and Merck Sharp & Dohme; he receives grants from Janssen, Merck, Sharp & Dohme, Roche, and Novartis; he is on the speakers’ bureau for Merck Sharp & Dohme, Janssen, and BMS; and he receives travel support from Janssen, Gilead, Merck, Sharp & Dohme, and Novartis. The trial was sponsored by Boehringer Ingelheim Pharmaceuticals. Dr. Younossi disclosed that he is an advisory committee/board member for Coneatus, Enterome, Gilead, Janssen, Salix, and Vertex.